

# Diabetes and Oral Health: Evidence, Mechanisms, and Clinical Implications

Arionget Jemima

Department of Pharmacoepidemiology Kampala International University Uganda  
Email: jemima.arionget@studwc.kiu.ac.ug

---

## ABSTRACT

Diabetes mellitus is a chronic metabolic disorder with wide-ranging systemic consequences, including profound effects on oral health. Accumulating evidence demonstrates a bidirectional relationship between diabetes and oral diseases, particularly periodontal disease, whereby poor glycaemic control exacerbates oral pathology and chronic oral inflammation adversely affects metabolic regulation. This review synthesizes current evidence on the epidemiology, mechanisms, and clinical implications of diabetes-related oral health complications. It examines the spectrum of oral manifestations associated with diabetes, including periodontal disease, gingival and periodontal infections, xerostomia, dental caries, altered oral microbiota, microvascular dysfunction, and impaired wound healing. Key pathophysiological mechanisms such as hyperglycaemia-induced immune dysregulation, advanced glycation end-product accumulation, oxidative stress, inflammatory cytokine networks, and vascular impairment are explored to elucidate the biological basis of these associations. The review further highlights the impact of periodontal disease and its treatment on glycaemic control, underscoring the clinical relevance of oral health in diabetes management. Special populations, including children, adolescents, and pregnant individuals, are discussed alongside public health, health literacy, and access-to-care considerations. Finally, the paper emphasizes the need for integrated medical-dental care models, routine oral health screening in diabetes care, and interprofessional collaboration. Addressing oral health as an integral component of diabetes management is essential for improving clinical outcomes, reducing systemic inflammation, and enhancing overall quality of life.

**Keywords:** Diabetes Mellitus, Oral Health, Periodontal Disease, Glycaemic Control, and Integrated Care.

---

## INTRODUCTION

Diabetes mellitus (DM) is recognized as one of the leading public health crises of the modern world. The World Health Organization (WHO) estimates roughly 420 million people are affected internationally, and by 2030, this figure will rise to an estimated 552 million people [1-8]. The link between diabetes and oral health has been acknowledged for many years. The diagnosis and management of diabetes in patients are often accompanied by a cascade of oral health complications [9-10]. These complications may be related directly to the pathophysiological changes of diabetes itself or to the effects of diabetes-related therapies. An oral-systemic connection is evident in which there is a bidirectional effect between glycemic control and the oral cavity [11-15]. Oral manifestations of diabetes are seen as the sixth complication of the disease, of which periodontal disease is the most evident and examined complication [16-20]. These consequences are influenced by a multitude of both local and systemic factors; nevertheless, the degree of oral complications observed in diabetic patients is directly correlated to the adequacy of the patient's metabolic control. A comprehensive overview of the association between diabetes and oral health, their implications, proposed explanatory mechanisms, and contemporary clinical strategies to mitigate these oral abnormalities is outlined in this study [21-24].

### Overview of Diabetes Mellitus

Diabetes mellitus (DM) is a chronic polyendocrine disorder characterized by hyperglycemia, stemming from  $\beta$ -cell impairment and/or reduced insulin response [25-28]. Its multifactorial etiology encompasses genetic and

environmental determinants, such as nutritional factors, infections, and epigenetic influences [29-34]. The International Diabetes Federation estimates that around 537 million adults aged 20-79 years worldwide had diabetes in 2021 and projects an increase to 643 million by 2030 and 783 million by 2045. Type 1 (T1D) is an autoimmune diabetes that results in absolute insulin deficiency and accounts for approximately 5-10% of cases, with onset typically occurring before adulthood [35-38]. Type 2 (T2D) is a heterogeneous disorder characterized by significant genetic and epigenetic predisposition and involves relative insulin deficiency and/or resistance [39-45]. It accounts for about 90% of diabetes cases and is usually diagnosed in adulthood, although the prevalence of pediatric and adolescent T2D is rising. Diabetes can also develop in pregnant individuals and is referred to as gestational diabetes mellitus [46-49].

### **Oral Health Outcomes Associated with Diabetes**

Diabetes is associated with a range of oral health-related issues, including periodontal disease, gingival and periodontal infections, xerostomia, increased caries risk, and microvascular complications affecting oral health [50-55]. These manifestations have been linked to poorer blood glucose control and can compromise diabetes management. Periodontal disease remains the most significant oral complication and is acknowledged as the sixth complication of diabetes [56-60]. Periodontal disease affects a substantial proportion of individuals with diabetes and is correlated with the extent of glycemic control [61-64]. Studies indicate that individuals with diabetes are 2.5 times more likely to experience periodontal disease when compared to non-diabetics, with advanced periodontitis being more prevalent. Destructive periodontal disease has been identified as a major local risk factor for individuals with diabetes [65-70].

### **Periodontal Disease**

Diabetes has significant implications for oral health, with periodontal disease being the most prevalent diabetes-related oral disease and a complication that worsens glucose control [71-76]. However, periodontal status is rarely assessed in diabetes care, and diabetes history is often not elicited when patients present with periodontal disease.

A bidirectional relationship exists between diabetes and periodontal disease [77-82]. Diabetics have a greater risk of periodontal disease and experience more rapid disease progression, leading to increased tooth loss, abscess formation, and complications during periodontal surgery. Conversely, diabetes can be a complication of periodontal disease, even in the absence of a pronounced systemic disease history [83-87]. Periodontal disease can disrupt glycemic control, with improved glycemic control succeeding periodontal treatment. The presence of oral bacterial infections has also been linked to metabolic syndrome, and oral pathogens can be detected in atherosclerotic plaques, potentially acting as a cofactor in atherogenesis [88-89]. Periodontal disease emerges as a major oral complication of diabetes, exacerbated by poor metabolic control. This chronic inflammatory condition of supporting periodontal tissues is driven by the accumulation of plaque, calculus, and other dental biofilms on tooth surfaces [90-93]. Susceptible individuals experience plaque-induced gingivitis and periodontitis, which can extend to dehydration, swelling of tissues, and tooth loss if left untreated. In diabetes, ongoing tissue impairment, benign neoplastic lesions, and primary and secondary candidiasis increase the risk of periodontitis [94-98].

### **Gingival and Periodontal Infections**

The inflammatory responses observed in gingival and periodontal infections are increased in diabetes mellitus 4. Even in the absence of periodontitis, individuals with diabetes display greater inflammatory responses than their non-diabetic counterparts [99-102]. The chronic inflammatory response triggered by diabetes is implicated in cardiovascular disease development. There is an association between chronic inflammatory states and the progression of severe periodontitis [103-108]. The microbial flora of dental plaque is known to play a key role in the development of periodontal disease. Plaque within periodontal pockets of gingivitis contains primarily gram-positive species, while anaerobic gram-negative pathogens such as *Actinobacillus actinomycetemcomitans*, *Porphyromonas gingivalis*, and *Prevotella intermedia* dominate deeper pockets. The continued presence of supra- and subgingival dental plaque on teeth or prosthetics maintains the inflammatory process. The presence of *P. gingivalis* and other periodontal pathogens is greater in the dental plaque of type 2 patients than in that of healthy individuals [109-110]. In patients with diabetes, increased glucose levels lead to an increase of gram-positive and non-fermentative species, such as *Staphylococcus epidermidis*, *Pseudomonas aeruginosa*, and *Acinetobacter baumannii*, in the oral cavity and on subgingival surfaces [5]. Patients with type 2 diabetes exhibit a distinct subgingival microbial composition different from both healthy individuals and patients with type 1 diabetes. Elevated concentrations of inflammatory markers such as sICAM-1, IL-1 $\beta$ , and TNF- $\alpha$  in periodontal tissues reflect increased microbial load and cytokine expression [2]. The microorganisms present in such patients are capable of inducing a wide range of pro-inflammatory cytokines. Diabetes promotes a hyperinflammatory response to different periodontal pathogens. Infected diabetic patches rouse a greater influx of neutrophils, macrophages, and T helper type 1 cells, resulting in increased tissue destruction. Bacterial proteases, lipopolysaccharides, and other toxins released during plaque accumulation degrade tissue and induce bone resorption [7]. Hyperglycaemia prevents normal intracellular signalling in neutrophils and alters phagocytic and bactericidal functions. In diabetic

individuals, both local and systemic immune pathways function at diminished capacity, eventually leading to diminished control over local periodontal pathogens and, therefore, augmented periodontal tissue destruction [9].

#### **Xerostomia and Salivary Changes**

Diabetes mellitus is associated with a number of oral health problems, including alterations in salivary flow and composition, leading to xerostomia or dry mouth [5]. Patients may experience not only persistent dryness but also other symptoms such as changes in taste sensation. Diabetic patients with xerostomia may have reduced salivary flow related to poor metabolic control, elevated HbA1c, and increased fasting blood glucose and other risk factors, including the use of certain medications [6]. Xerostomia can have a number of detrimental effects on overall oral health, and the condition appears to be associated with greater caries incidence, periodontal disease, discomfort due to denture use, and impaired speech [9]. The salivary gland parenchyma may undergo structural and functional alterations in individuals with diabetes, resulting in a decrease in salivary flow [3]. Neuropathy affecting salivary glands, the presence of advanced glycation end products, and blood vessel impairment due to diabetes-related angiopathy may also contribute to diminished salivary secretion [5]. Decreased salivary flow can lead to hyposalivation and eventually xerostomia, or an almost complete absence of salivary output [1].

#### **Caries Risk and Microbial Shifts**

In diabetic subjects, the hazard of demineralization, particularly of the tooth's surface, may be heightened, a phenomenon closely interlinked with hydration [7]. When salivary concentrations of glucose, which exist above baseline levels, also prevail, the count of cariogenic species is prompted to rise. Notably, the cariogenic role of these species manifests through local acid production that extends into biofilm [8]. Furthermore, dental biofilms taken from people with diabetes harbor an overabundance of microorganisms from categories known to influence caries [9]. Strong partners, both in disease and the public domain, exhibit varied salivary compositional features depending on whether the host is diabetic [10].

#### **Microvascular and Healing Considerations**

Diabetes mellitus is a chronic metabolic disorder that is characterized by hyperglycemia due to a deficit of insulin secretion, action, or both [2]. It causes microvascular and macrovascular complications, which include diabetic parodontopathy. There is a strong association between diabetes and periodontal disease that has been attributed to damaging alterations of microcirculation in the periodontium and oral mucosa [9]. Hyperglycemia determines the excessive production of reactive oxygen species, which induces oxidative stress. Oxidative stress increases protein glycation and oxidation, which are factors associated with atherosclerosis and microangiopathic phenomena. Characteristic manifestations of microcirculatory damage at the oral mucosa level are tissue atrophy and an increase in periodontal disease, which is also partially caused by the excessive glucose concentration in the sulcular fluid [7]. The alterations at the microcirculation level can be *in vivo* analyzed by videocapillaroscopy, which allows the examination of capillaries' morphology and dynamics, including diameter, crossing, and density [6]. These parameters may have predictive value from the clinical point of view. However, no *in vivo* study has so far demonstrated an explicit connection between the variations of periodontal microcirculation and diabetic pathology. Capillaroscopic examination should be carried out on the oral mucosa, which is an accessible site for the study of patients [9]. Individuals with type 2 diabetes have been found to show macrovascular, microvascular, and metabolic complications related to increased glucose levels in different biological fluids, such as plasma, serum, and urine [6]. The periodontium is also accessible to capillaroscopy. Based on the considerations mentioned above, a study was carried out to identify and analyze microcirculatory variations at the periodontal mucosa in a population of subjects with type 2 diabetes [3].

#### **Pathophysiological Mechanisms Linking Diabetes and Oral Health**

Diabetes is a global health concern, and its prevalence is expected to rise significantly in the coming decades. Diabetes mellitus comprises a group of metabolic disorders characterized by chronic hyperglycemia resulting from defects in insulin secretion, insulin action, or both [3]. There are two major forms: type 1 diabetes, in which pancreatic  $\beta$ -cells are destroyed, leading to insulin deficiency, and type 2 diabetes, known for multifactorial aetiologies, including a combination of insulin resistance and defective insulin secretion, which often co-presents with obesity [15]. The concentration of glucose in the blood is maintained within narrow limits through a feedback mechanism coordinated by hormones such as insulin, glucagon, somatostatin, and catecholamines. Prolonged dysregulation triggers diabetes-associated pathophysiological changes, such as microvascular complications affecting the retina and kidney, peripheral vascular insufficiency, cardiovascular pathophysiology, delayed wound healing, and impaired immune response [11]. Such complications magnify patient risk for oral health-related issues and amplify attacks on dental and periodontal structures [4]. Glycemic control begun upon initial diagnosis and consistently pursued plays a significant role in mitigating these complications and, thus, is of pivotal importance. Therefore, the oral cavity should act as a crucial point of focus for health inspections, assessments, and feedback regarding the plight of the diabetic patients and their intimate relationship with evolving diabetes care [12]. Pathological transformations also encounter the oral cavity at various stages and

magnitudes during various oral and systemic events associated with uncontrolled high-risk diabetes and later-stage pre-diabetes [10].

### **Hyperglycemia and Advanced Glycation End-Products**

Elevated levels of glucose and advanced glycation end-products (AGEs) are hallmarks of diabetes, responsible for several complications [9]. At normal glycemic levels, glucose is low enough that endogenous AGE formation catalyzed by glucose at free amino groups of proteins, lipids, and nucleic acids occurs relatively slowly [11]. AGEs can also be formed from other sources, including nicotine, pyrraline, methylglyoxal, oxo-dehydroglucose, and lead, among others, through non-enzymatic processes like Amadori rearrangement and caramelization (Chopra et al., 2022)[12]. The body has several systems for degrading these products, and AGEs can improve the biological properties of proteins, extend the half-lives of glycosylated proteins, and act as viability signals for cells [16]. Tissue concentrations of AGEs rapidly increase under elevated glucose levels, becoming detrimental (Chopra et al., 2022). For instance, it was demonstrated in a study in T1DM<sup>1</sup> that AGEs accumulate in lamina propria and corneal epithelium, causing approx[13]. 1.5- and 2-fold increases in skin fluorescence in T2DM. Sources of extracellular AGEs include proteins infiltrating from plasma and glycosylated/non-glycosylated proteins, their half-lives being considerably expanded under hyperglycemic conditions (Chopra et al., 2022)[11]. AGEs stimulate various receptors (e.g., RAGE), triggering inflammation, apoptosis, vascular leakage, and accelerating the development of diabetic complications. Hyperglycemia-induced DAG synthesis activates PKC isozymes in vascular cells, thereby also promoting inflammation and other mechanisms through other compounds and pathways [2]. Fluorophotometric measurements in another study of T1DM indicated that the eye-glucose barrier can be breached by AGEs (Chopra et al., 2022). Accordingly, AGEs contribute to hyperglycemia-induced early ocular complications in DM. AGEs produced in inflamed periodontal tissues were shown to be responsible for systemic elevation of AGEs in individuals with or without diabetes (Chopra et al., 2022)[3]. Individuals exhibiting periodontitis have higher AGE levels in serum, saliva, gingival crevicular fluid, tissue, and combined diabetes/periodontitis involvement leads to greater systemic AGE elevations than either condition alone [5].

### **Inflammatory Pathways and Cytokine Networks**

Glycemic imbalance produces important changes in the immune system that affect host responses to infection and enhance tissue destruction [2]. Systemic effects of diabetes, including impaired immune response, altered salivary function, and impaired wound healing, promote the onset, severity, and progression of oral diseases, including infections and periodontal disease [12]. Immuno-inflammatory mediators, such as cytokines, are produced in the diabetic host in response to multiple stimuli, including microbiota dysbiosis in the oral cavity, and induce tissue damage and bone resorption in multiple organs. Periodontal pathogens contribute to the pathogenesis of diabetes through diverse inflammatory pathways [5]. Confirmatory evidences include sustained elevations of specific immunological components related to diabetes observed after oral infection, which, in turn, induces modifications of the oral biofilm conducive to other opportunistic infections [9]. The pandemic of diabetes mellitus (DM) is affecting millions of people worldwide. Since the beginning of the 21st century, China has overtaken the USA to become the country with the most people with diabetes. DM is a heterogeneous group of disorders characterized by hyperglycemia due to defects in glucose homeostasis [13]. Type 1 DM is characterized by insufficient insulin production, whereas Type 2 DM, the most prevalent form, may have an initially normal or even high-serum insulin level but is accompanied by [2] the lack of efficiency of the secreted hormone to elicit a physiological response, [1] increased production of insulin combined with altered insulin clearance, or [3] the action of various biological pathophysiological processes responsible for the eventual depletion of the original insulin supply [15]. Metabolic syndrome, a disease that affects the majority of Type 2 DM patients, is associated with Pre-Diabetes and progresses from Insulin Resistance to overt clinical stages where a variety of bioactive lipids accumulate, triggering further downstream inflammation [5]. The disease is characterized by high blood sugar levels due to a lack of insulin, insulin resistance, or other causes, and has a wide range of tissue and organ complications, such as cardiovascular disease, nephropathy, retinopathy, neuropathy, and poor wound healing [13].

### **Salivary Alterations and Oral Microbiome**

Long-term hyperglycemia in diabetes leads to the development and progressive accumulation of advanced glycation end-products (AGEs), generation of reactive carbonyl precursors, and post-translational protein modifications that induce morphological, structural, and functional changes in salivary glands, notably the parotid gland [13]. These changes impair salivary secretion; alter the concentration of specific proteins, electrolytes, nitric oxide (NO), and other metabolites; and induce increased dehydration, viscosity, and lability of saliva [7]. Consequently, saliva substitutes, moisturizers, and stimulants that are commonly prescribed for xerostomia provide only partial relief [8]. Within the oral cavity, diabetic hyperglycemia alters the composition of the salivary microbiome, salivary metabolites, and the pH of saliva. At both the systemic and local levels, diabetes influences the immune and inflammatory response; increases the risk of infection through alterations of the plasma and salivary proteomic profiles; and modifies the bioavailability of key signalling molecules such as reactive oxygen species (ROS) and nitric oxide (NO) [14]. These effects, combined with a reduced pH and increased

viscosity of saliva, may promote the transition from health to disease following infection of vital organs and tissues, including the oral cavity [13].

#### **Vascular and Wound-Healing Impairments**

Impaired vascular integrity and compromised wound healing are common consequences of diabetes mellitus. Endothelial dysfunction plays a pivotal role in vascular complications and leads to macrovascular and microvascular diseases such as retinopathy [11]. Diabetes increases the risk of infection and prolongs the healing process due to immune dysfunction, including abnormalities and impaired chemotaxis of neutrophils. In patients with diabetes, dental treatment often results in delayed healing, with defects in neutrophil activation, fibroblast migration, proliferation, and angiogenesis [15]. Advanced glycation end-products accumulate in gingival tissues, potentially contributing to tissue injury by interfering with matrix-cell interactions [12].

#### **Bidirectional Relationships: Oral Health Impact on Glycemic Control**

The interrelationship between periodontal disease and diabetes has been described as bidirectional. Clinical and epidemiological studies demonstrate not only that poorly controlled diabetes increases the risk of periodontal disease, but also that periodontal therapy can significantly lower glycated hemoglobin (HbA1c) levels [16]. Individuals with diabetes exhibit higher frequencies of periodontal disease, gingival inflammation, and oral complications than those without [17]. Societal frameworks employed for diabetes care present relevant diagnostics and therapeutics for examination of these relationships [2]. Periodontal treatment reduces HbA1c levels by an average of 0.38% over periods ranging from 1.5 to 24 months, achieving significance in most studies. The relationship between oral infections and systemic inflammation may represent a crucial pathway for the influence of oral health on diabetes [6]. Periodontopathic bacteria and their extracellular products can enter the bloodstream and stimulate production of interleukin (IL)-1 $\beta$  and IL-6, which induce hepatic production of fibrinogen and C-reactive protein (CRP) [7].

#### **Influence of Periodontal Therapy on HbA1c**

Periodontitis is a chronic inflammatory disease that affects the supporting tissues of the teeth. It is characterized by periodontal pocket formation, gingival recession, and loss of connective tissue attachment to root surfaces. Diabetic patients have a higher prevalence and severity of periodontal diseases than nondiabetic individuals [2]. Diabetes is still a major problem in the world [17]. It is a noncommunicable disease that has high prevalence and mortality [11]. Periodontal disease is also a major concern for the world currently. It affects a large population throughout the world. Many studies have been done to assess the effect of diabetes on periodontal disease. Markedly elevated levels of glycosylated hemoglobin A1c (HbA1c) provide evidence of poor glycemic control [3]. According to the American Diabetes Association (ADA), HbA1c can be used to measure the 3-month average of carbohydrate intake and metabolic control in patients. It represents a significant measure in the progression of diabetes. Strict control of glucose levels is essential in establishing a healthy life [5]. Diabetes can enhance susceptibility to various infections and can impede the healing of wounds in diverse sites of the body, including the oral cavity. Diabetic patients have a higher prevalence of oral diseases and infections; periodontal disease appears to have a close association with diabetes among all of these problems [7]. Periodontal disease affects not only the oral cavity but can also reflect the overall health status of the patient; that is, periodontal disease can be considered as a manifestation of systemic disease [4]. Periodontal disease might adversely affect the control of glucose levels. The association between periodontal disease and diabetes has suggested that periodontal treatment is likely to have an effect on the glycemic control of diabetic patients [18, 19].

#### **Impact of Oral Infections on Systemic Inflammation**

Periodontal pathogens that penetrate the bloodstream during gingival inflammation can impact distant tissues involved in energy homeostasis [21]. This influence constitutes a relevant mechanism for the bidirectional connection between diabetes and periodontitis [20]. In type 2 diabetes, prolonged hyperglycemia alters metabolic pathways and activates the formation of advanced glycation end products (AGEs). Such compounds elevate the secretion of proinflammatory mediators by immune cells and compromise the functionality of macrophages, dendritic cells, and neutrophils, causing further tissue damage [22]. Increased circulating levels of proinflammatory substances such as tumor necrosis factor- $\alpha$  (TNF- $\alpha$ ), interleukin-6 (IL-6), and C-reactive protein (CRP) by the host lie at the heart of the relationship between diabetes and periodontal disease [23]. These factors aggravate metabolic control, intensify microvascular complications, and render type 2 diabetes more difficult to manage [21].

#### **Clinical Assessment and Risk Stratification**

Regular screening for oral health problems should be considered an integral component of diabetes care [22, 23]. Periodontal disease and other oral health disorders negatively impact the quality of life in diabetic individuals. Further, the presence of oral disease could contribute to poor glycemic control, increased systemic inflammatory burden, and heightened cardiovascular disease risk [16]. The American Dental Association endorses the consideration of whether a person has, or is at risk of developing, a dental disease or condition as one of the six key clinical conditions that constitute indicators of overall health. Consequently, oral health status should be included

in the assessment of persons with diabetes [2]. Periodontal involvement or candidiasis may be taken as indicators of poorly controlled diabetes during initial or subsequent visits. Individuals with diabetes are known to be at increased risk of oral health problems stemming from abnormal salivary function, poor oral hygiene practices, and a high dietary intake of fermentable carbohydrates [4]. Periodontal health status, number of remaining teeth, oral hygiene practices, salivary function, and frequency of dental visits therefore represent appropriate screening indicators for the identification of oral disease risk, the understanding of diabetes-related oral complications, and, ideally, the initiation of interprofessional collaboration or referral [6]. The presence of advanced periodontal disease and excessive tooth loss following periodontal disease is also associated with increased cardiovascular disease risk both in the general population and in populations characterized by a high prevalence of diabetes [7].

#### **Screening for Oral Health in Diabetes Care**

Diabetes has been shown to exacerbate oral diseases, including periodontal disease, especially in individuals with poor glycemic control [1]. The ability of oral diseases to negatively impact glycemic control adds a further dimension to the interrelationship between diabetes and oral health, making screening for oral health and the provision of goal-oriented oral health care critical in diabetes management [16]. Such screening should be performed at the time of initial diagnosis and at subsequent routine health care visits.

#### **Diagnostic Indicators and Monitoring**

In addition to the oral health complications associated with diabetes mellitus, underlying factors contributing to these adverse outcomes have been identified [3]. One means of detecting such changes involves the monitoring of specific biomarkers in saliva and blood [3]. When assessing paraclinical evolution or the efficacy of anti-diabetic therapy, monitoring blood levels of glycated hemoglobin (HbA1c) represents a standard procedure [6]. The concentrations of this hemoglobin derivative furnish information about glucose variability over previous weeks and enable the definition of hyperglycemia-based metabolic control, being an indirect indicator of periodontal condition [1]. Following the first months of diabetes treatment, the objective for HbA1c improvement is hence determined. The relative reduction sought for this marker can be used to classify patients into different metabolic control categories, taking into account the level of glycemic control before diabetes therapy was introduced [6]. Periodontal pathologies have also been correlated to the presence of salivary indices linked to the glycemic status of individuals, notably salivary glucose [6].

#### **Inter-professional Collaboration and Care Pathways**

Healthcare professionals play a vital role in screening for oral health conditions in patients with diabetes. Numerous studies have explored how and when oral health is focused on within diabetes care [24]. One study reported that primary care physicians seldom ask about the oral health of patients with diabetes. This is partly attributed to a perception that such inquiries are not relevant and a view that patients already receive any necessary oral healthcare [23]. Dental health services, on the other hand, largely lack specific protocols for analyzing diabetes hazards. Consequently, diabetes has little impact on the assessment of oral health, despite the existence of considerable evidence indicating a connection [22]. Many dental health providers do not routinely question patients about diabetes, and even those who conduct glucose testing report discrepancies in the condition's influence on treatment [21]. Patients with diabetes are often unaware of the association between their condition and oral health. They seek more information about how periodontal treatment can improve glycaemic control, desire assistance in managing their disease, and value discussions with healthcare professionals about both the disease itself and oral hygiene [19]. Integrating topics related to diabetes and oral health into a patient's overall wellness can improve motivation. Attention to oral health can enhance patient engagement in diabetes treatment programmes [18]. Patients are also concerned that appropriate management of gum disease may reduce ongoing complications due to dental treatment. Greater awareness about the relationship connecting diabetes and oral health could help patients make educated decisions about both [17].

#### **Management and Intervention Strategies**

The management and intervention strategies reported emphasize preventive methods and treatment alternatives that target both diabetes and its oral health ramifications. Individuals suffering from tooth loss and those who self-assess their oral health unfavorably face a heightened risk of ischemic stroke, additional vascular disorders, and increased mortality rates [25]. Hence, individualized wellness and health agendas aimed at curtailing obesity emergence or progress are warranted, given obesity's established links to diabetes and other chronic conditions [26]. Certain periodontal therapies, including non-surgical periodontal treatment (NSPT) augmented with adjunctive photodynamic therapy and doxycycline, effectively reduce glycated hemoglobin (HbA1c) levels in non-smoking patients who also present periodontal disease [11]. Gaseous ozone treatment further benefits patients experiencing both diabetes and periodontitis [12]. Moreover, access to oral healthcare remains notably limited for residents of assisted living facilities, reinforcing policy advocacy's importance [11]. Educational strategies such as role-playing pharmaceutical consultations serve to enhance health professionals' knowledge and motivation surrounding diabetes, while interventions introducing dental hygienists to palliative care promote both career development and improvement of patients' quality of life [10]. Risks to oral hygiene frequently arise among

college students, highlighting the necessity for dedicated awareness campaigns targeting this demographic [19]. More generally, preventive approaches addressing both environmental and genetic determinants, thereby preventing and arresting the onset of diabetes, its complications, and concomitant oral health issues, constitute a primary line of action [8]. Comprehensive diabetes management and treatment orbited around glycemic control and systemic factors substantially mitigate the risk of oral conditions [14]. Health practitioners, especially general medical doctors and nurse practitioners, thus bear crucial responsibilities in both the clarification of oral health's implications in diabetes and the constituent engagement of patients in therapeutic strategies [17].

#### **Preventive Dentistry in Diabetes**

Patients with diabetes are at heightened risk for oral health complications, yet information on appropriate dental care remains insufficiently integrated into diabetes care [13]. Although certain diabetes medications can exacerbate periodontal disease, other medicines such as metformin, glucagon-like peptide-1 receptor agonists, and sodium-glucose co-transporter-2 inhibitors exert an overall prophylactic effect [5]. Consequently, dental health professionals should employ teaching and counselling strategies focusing on self-care and on the management of specific complications, including dry mouth, oral candidiasis, dysgeusia, and periodontal disease. Referral pathways for diabetes prevention and management should furthermore be enhanced and strengthened [1, 16].

#### **Periodontal Therapy and Glycemic Outcomes**

Severe periodontal disease represents a significant oral health complication for individuals with diabetes mellitus. As evidenced by clinical improvements following therapy, active periodontal disease may negatively impact glycemic control [18]. Widths of keratinised gingival tissue, probing depth, and clinical attachment levels in patients with type 2 diabetes and periodontal disease improve after nonsurgical periodontal therapy. Improvements in clinical and glycemic parameters are apparent as early as three months post-treatment [27]. Bacteriological studies and records of diabetes history prior to the onset of periodontal disease suggest the systemic impact of periodontal infection [20].

#### **Patient Education and Self-Care**

The provision of information about diabetes-related oral complications, specific sugary dietary risk factors, dietary replacements for sugary products, tobacco cessation assistance for periodontal health, smoking addiction and periodontal disease awareness, and clarifications regarding early-periodontally-influenced diabetes was consistently substandard [2]. Public health initiatives and instructional programs that stress the necessity of oral examinations, the oral impact of diabetes on both esthetics and quality of life, and the need for interprofessional assistance could greatly benefit affected populations [28]. Adherence to prescribed pharmacological treatment regimens and the link between temporal control of blood glucose and the prevention of complications merit patient educational emphasis. Periodontal disease impacts diabetic control [29]. Educational programs that address the reciprocal effects of diabetes and periodontal health may enhance compliance with proper oral hygiene measures. Individuals with diabetes often bear a greater risk for oral disease [25]. Oral health also significantly affects the course of diabetes, as infections and inflammatory conditions provoke systemic mediators that may elevate blood glucose [31]. Conversely, a low level of understanding regarding the impact of oral health on diabetes is proportionately correlated with reduced diabetological condition awareness. Health professionals engaged in diabetes management should underscore the importance of oral health and recommend regular dental visits to facilitate early diagnosis of potentially diabetic complications [2].

#### **Medication Considerations and Safety**

Dental practitioners need to be aware of the medication-related side effects experienced by their patients. Diabetes patients are prescribed various medications that can induce side effects affecting the oral cavity and complicating dental treatment [6]. Medication-related oral effects should mainly be considered for patients receiving insulin, antihyperglycemic medications, polypharmacy treatments, and psychotropic agents [3]. Insulin preparations induce oral side effects such as burning mouth syndrome, taste disturbance, oral discomfort, swelling, and vesicle lesions. Antihyperglycemic medicines may cause oral candidiasis or cytotoxicities in the hard and soft tissues; therefore, routine follow-ups are needed [4]. Oral side effects of antihyperglycemic drugs include dysgeusia, burning mouth syndrome, dry mouth, and slowed wound healing [3]. Psychotropic medications used to treat anxiety and depression constitute some of the most widely prescribed drugs among diabetic patients. Careful assessment of the oral side effects caused by these medications is recommended; otherwise, the patient's health may be compromised [3].

#### **Special Populations and Considerations**

Type 1 (T1D) and type 2 diabetes mellitus (T2D) represent distinct diseases with unique pathophysiologies, while sharing epidemiologic and clinical features [9]. The overall prevalence of oral health conditions associated with diabetes, as well as their systemic impact, is higher in T2D than T1D due to the longer duration of illness, the concomitant metabolic syndrome, and the more severe level of hyperglycemia [8]. Multivariate models support that T2D rather than T1D is independently associated with an increased risk of periodontal disease in subjects without other health issues [7]. The frequency of caries is, in general, higher in T1D than in T2D, partly due to

different social habits, as well as intrinsic factors such as the depletion of salivary flow or a more frequent history of oral infections [16].

#### Pediatric and Adolescent Patients

Diabetes is currently diagnosed and treated in children and adolescents, allowing the results of its oral implications to be evaluated in the early stages of the disease [10]. Subjects at the onset of T2D who consulted a dentist at the time of diagnosis had already experienced at least one episode of oral inflammation. Thermography studies demonstrated that dental pulp inflammation can occur in T2D within the first few months of the onset of the disease [30].

#### Pregnant Individuals with Diabetes

Women who had preexisting diabetes prior to conception or who developed gestational diabetes are prone to developing oral conditions (e.g., gingivitis, periodontitis, and dental caries) during pregnancy [13]. Dental checks and advice should be encouraged before, during, and after pregnancy in such patients for oral health maintenance as well as for the prevention of fetal complications [14].

#### Type 1 versus Type 2 Diabetes

The extractions have clarified and expanded aspects of the bidirectional interplay between diabetes and oral health, as well as management strategies, while further developing sections focused on special populations and public health [17]. Type 1 and Type 2 Diabetes provide new information about distinct physiological differences that could drive different oral health outcomes in diabetes. Other sections introduce new material based on relevance to diabetes and oral health [16]. The result is a broader yet still focused treatment of the overall topic. Common misconceptions persist about the differences between T1D and T2D. T1D can occur at any age and typically appears during childhood or adolescence; however, T2D is increasingly seen in children and adolescents, largely as a consequence of the rising prevalence of childhood obesity and sedentary lifestyles [11]. Much research has focused on children and adolescents with T1D, but the incidence of T2D in such populations has grown alarmingly [23]. These trends likely affect oral health outcomes, yet few studies have systematically examined the oral health components of T1D and T2D, particularly among children and adolescents [10]. Periodontal inflammation has been proposed as a potential contributing factor to the destruction of pancreatic  $\beta$ -cells in T1D [31]. Preclinical models indicated that an inflammatory mechanism could sustain and amplify  $\beta$ -cell destruction initiated by autoimmune processes [18]. One study reported that the glycosylated hemoglobin (HbA1c) levels of children and adolescents with T1D and periodontitis were higher than those of children without periodontitis. Prior to periodontal therapy, children with T1D plus periodontitis exhibited worse glycemic control than children with T2D and periodontitis; however, this difference disappeared after treatment [19]. These findings suggest that periodontal disease might represent a risk factor for poor glycemic control in young people with T1D. Conversely, limited evidence from children and adolescents suffering from T2D and periodontal disease indicated no significant food intake deviations from corresponding children with T2D and good periodontal health [11]. Further investigation into age, sex, oral hygiene practices, and dietary habits may elucidate potential gender differences regarding childhood periodontal disease and the relationship between diabetes and childhood periodontal disease [12].

#### Pediatric and Adolescent Patients

Insufficient diabetic management during childhood carries serious health implications, and oral health constitutes an especially important area of concern [19]. Diabetes is often accompanied by complications involving the kidneys, eyes, and cardiovascular system, prompting needs for interprofessional treatment. Children with type 1 diabetes show elevated standard deviation scores for red and inflamed gum levels and various other periodontal health measures [32]. Existing oral conditions are worsened by persistently high glycosylated hemoglobin (HbA1c) values and metabolic decompensation episodes [20]. In adolescents with diabetes, associations exist between periodontal disease and additional damage to oral health, such as caries, causing both soft-tissue and hard-tissue loss. For this reason, heightened attention is needed concerning appropriate oral hygiene measures among youth with diabetes [18].

#### Pregnant Individuals with Diabetes

The burden of gestational diabetes mellitus (GDM) has increased globally, raising awareness of its effects on oral health. Individuals with GDM generally show poorer oral health than their non-diabetic counterparts, likely due to more complex lifestyle, diet, and dental treatment histories [33]. An investigation of salivary microbiota and nutrient profile further reveals that salivary glucose monitoring may reflect metabolic control lapses during pregnancy, even in women diagnosed with GDM well before conception [34]. The early shift in carotenoids towards  $\beta$ -carotene and later adjustment of amino acids, on the contrary, occurs only in GDM-affected pregnancies [33]. Potential reasons for such divergence include dietary alterations associated with excessive weight gain during this sensitive period [22]. Considering the pervasive physiological and hormonal transitions accompanying gestation and their interactions with diabetes, dental professionals should pay close attention to the

oral healthcare needs of at-risk pregnant individuals and routinely consult on general health during preventive examinations [20].

### **Public Health Perspectives and Policy Implications**

Dr. L.G. G. Astek enunciated the need to promote public awareness regarding oral health, specifically for diabetes patients [20]. In this regard, studies revealed that most patients are unaware of the high glucose/fragility of the oral cavity and major oral hygiene strategies to apply. Research showed a lack of financial protection for dental services after a diabetes diagnosis, due to high costs [12]. Enhancement of oral health education, screening services, dental-service packages, and policy prioritization is of prime importance [23]. The Ministry of Health should place further focus on the prevention of diabetes and oral health problems [12]. Healthcare systems should fortify preventive and management strategy arrangements through the prevalence of diabetes, along with interprofessional and interdisciplinary integration promotion to resolve both oral and systemic health-related matters [25, 30].

### **Access to Care and Health Literacy**

The condition of oral health in people with diabetes is informed not only by biomedical factors but also by social factors, including access to prevention and treatment services, use of preventive dental services, professional dental cleaning, and endorsement of self-care practices [27]. There is a growing recognition that higher levels of health literacy enable individuals to obtain effective preventive and therapeutic care because they possess the skills and critical thinking to navigate resource-constrained environments and lifestyles that challenge acquisition and maintenance of oral health [35]. In people with diabetes, limited knowledge and inappropriate oral health behaviours adversely affect both diabetes and oral health outcomes [36]. Access to dental care throughout their lives is poorer among many in minority and economically disadvantaged groups, even when educational attainment is similar [31]. For people with diabetes, oral health signs and symptoms that arise throughout the continuum of the disease are rarely sought for care until major damage has occurred [30]. Because of the conception of oral health as a relatively low public health priority, many health agencies and policy-makers fail to recognize oral health as an integral component of overall health and wellness, or neglect education on access to dental care as part of strategic health promotion efforts [29]. Further pooling of public health resources, such as for the COVID-19 pandemic, dilutes what meagre investment exists for oral health topics and exacerbates associated risks [32].

### **Integrated Care Models**

People with diabetes are at increased risk for oral diseases; conversely, oral diseases are associated with poorer glycemic control [33]. These mutual relationships provide good reasons for fostering integrated medical-dental care. A pilot study in 6 states explored the integration of chronic disease programs across multiple domains, yielding lessons applicable to the diabetes-oral health nexus [37]. Another longitudinal project in community health centers with federally qualified health center dental safety net clinics demonstrated the potential of point-of-care glycemic screening to facilitate access to comprehensive chronic disease care, benefiting both diabetes and periodontal disease [38].

### **Research Gaps and Future Directions**

Although studies have demonstrated the need for integration of diabetes and oral health care, considerable gaps remain [39]. The substantial evidence of a relationship between diabetes and periodontitis [39] has not resulted in a paradigm shift for many health professionals [21]. The challenge remains even greater for other oral health-diabetes links, for which the evidence base is more limited. Neither the quantity of work nor its attention from the dental community has translated into robust knowledge by the medical profession [30]. Siloed practice continues to hinder collaboration and communication between the two groups, while linguistic barriers and a lack of awareness of key bibliometric terms restrict outreach to non-specialists, as does the proliferation of predatory journals. The need for further investigation remains pressing [38-48]. Longitudinal studies are warranted to clarify the manifestation, progression, and timing of oral complications in diabetes, as well as to identify putative sex-specific and drug-specific differences [34]. Exploration of risk-reduction strategies, alongside the pathways that underpin diabetes-related oral alterations in particular populations, such as the mechanically ventilated, is also essential [37]. Biobanks and omics-based research, supplemented by health economics studies, may elucidate the biological and economic links between diabetes and oral health. Patient-centered outcomes and qualitative methods are likewise deserving of greater focus [36].

### **CONCLUSION**

Diabetes mellitus exerts a significant and multifaceted impact on oral health, with periodontal disease emerging as the most prevalent and clinically significant oral complication. The evidence presented in this review reinforces the concept of a bidirectional relationship between diabetes and oral disease, in which hyperglycaemia-driven immune dysfunction, inflammatory pathways, advanced glycation end-product accumulation, and microvascular impairment contribute to oral pathology, while chronic oral infections further exacerbate systemic inflammation and compromise glycaemic control. These interactions underscore the oral cavity as both a target and a contributor to the progression of diabetes. Clinical findings consistently demonstrate that individuals with poorly

controlled diabetes experience more severe oral complications, including periodontal disease, xerostomia, caries, delayed wound healing, and altered oral microbiota. Conversely, effective periodontal therapy has been shown to produce modest but clinically meaningful reductions in HbA1c levels, highlighting the importance of oral health interventions as an adjunct to diabetes management. Despite this strong evidence base, oral health assessment remains insufficiently integrated into routine diabetes care, and awareness of the diabetes–oral health connection among both patients and healthcare professionals remains limited. From a public health and policy perspective, improving outcomes requires a shift toward integrated medical-dental care models, enhanced health literacy, routine oral health screening, and improved access to preventive and therapeutic dental services, particularly for vulnerable and underserved populations. Interprofessional collaboration between medical and dental practitioners is essential to bridge existing care gaps and ensure early identification and management of oral complications. In conclusion, recognizing oral health as an integral component of diabetes care is critical for reducing disease burden, preventing complications, and improving quality of life. Future research should prioritize longitudinal and translational studies, explore population-specific risk factors, and evaluate cost-effective integrated care strategies. A holistic, patient-centred approach that addresses both metabolic control and oral health holds substantial promise for improving long-term outcomes in individuals living with diabetes.

## REFERENCES

1. Mauri-Obradors E, Estrugo-Devesa A, Jané-Salas E, Viñas M, López-López J. Oral manifestations of Diabetes Mellitus. A systematic review. *Medicina oral, patología oral y cirugía bucal*. 2017 Aug 16;22(5):e586.
2. Mauri-Obradors E, Estrugo-Devesa A, Jané-Salas E, Viñas M, López-López J. Oral manifestations of Diabetes Mellitus. A systematic review. *Medicina oral, patología oral y cirugía bucal*. 2017 Aug 16;22(5):e586.
3. Ugwu OP, Ogenyi FC, Ugwu CN, Basajja M, Okon MB. Mitochondrial stress bridge: Could muscle-derived extracellular vesicles be the missing link between sarcopenia, insulin resistance, and chemotherapy-induced cardiotoxicity?. *Biomedicine & Pharmacotherapy*. 2025 Dec 1;193:118814.
4. Surlari Z, Ciurcanu OE, Budala DG, Butnaru O, Luchian I. An update on the interdisciplinary dental care approach for geriatric diabetic patients. *Geriatrics*. 2023 Nov 25;8(6):114.
5. Kong YR, Jong YX, Balakrishnan M, Bok ZK, Weng JK, Tay KC, Goh BH, Ong YS, Chan KG, Lee LH, Khaw KY. Beneficial role of *Carica papaya* extracts and phytochemicals on oxidative stress and related diseases: a mini review. *Biology*. 2021. 10: 287. *Bioactivity of Medicinal Plants and Extracts*. 2021:143.
6. Sonpanao P, Janebodin K, Namvichaisirikul N, Thongjit S, Jitprasertwong P. The Prevalence of Xerostomia in Older Thai Individuals with Type II Diabetes Mellitus and Its Association with Type of Toothpaste and Oral Functions: A Cross-Sectional Study Using Questionnaires. *Geriatrics*. 2023 Jul 15;8(4):76.
7. Paul-Chima UO, Nneoma UC, Bulhan S. Metabolic immunobridge: Could adipose-derived extracellular vesicles be the missing link between obesity, autoimmunity, and drug-induced hepatotoxicity?. *Medical Hypotheses*. 2025 Sep 28;111776.
8. Susanto H, Agustina D, Abbas F, Vissink A. Xerostomia, glucose regulation and serum inflammatory markers in Indonesians with type 2 diabetes mellitus. *Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology*. 2015 Mar 1;119(3):e112.
9. Negrini TD, Carlos IZ, Duque C, Caiaffa KS, Arthur RA. Interplay among the oral microbiome, oral cavity conditions, the host immune response, diabetes mellitus, and its associated-risk factors—An overview. *Frontiers in oral health*. 2021 Sep 9;2:697428.
10. Spatafora G, Li Y, He X, Cowan A, Tanner AC. The evolving microbiome of dental caries. *Microorganisms*. 2024 Jan 7;12(1):121.
11. Ifie SE, Dangana RS, Swase D, Ben Okon M, Makena W, Agunloye MO, Ugwu CN, Ifie JE, Odoma S, Babangida AI, Aja PM. Nutritional composition of *Zea mays* L: A comprehensive Review of Macronutrients, Micronutrients, and Bioactive Compounds. *Open Research Africa*. 2025 Sep 10;8:15.
12. Scardina GA, Cacioppo A, Messina P. Periodontal microcirculation in diabetics: an in vivo non-invasive analysis by means of videocapillaroscopy. *Medical Science Monitor: International Medical Journal of Experimental and Clinical Research*. 2012 Feb 1;18(2):CR58.
13. Grover HS, Luthra S. Molecular mechanisms involved in the bidirectional relationship between diabetes mellitus and periodontal disease. *Journal of Indian Society of Periodontology*. 2013 May 1;17(3):292-301.
14. Verhulst MJ, Loos BG, Gerdes VE, Teeuw WJ. Evaluating all potential oral complications of diabetes mellitus. *Frontiers in endocrinology*. 2019 Feb 18;10:56.
15. Ugwu OP, Ogenyi FC, Ugwu CN, Ugwu MN. Gut microbiota-derived metabolites as early biomarkers for childhood obesity: A policy commentary from urban African populations. *Obesity Medicine*. 2025 Sep 1;57:100641.
16. Velea OA, Kraliev C, Onisei D, Onisei D, Nica LM, Velea IP. Diabetes mellitus and periodontal disease—a two-way road: current concepts and future considerations (literature review). *European Scientific Journal*. 2013 Mar 31;9(9).

17. Duarte PM, Gurgel BC, Miranda TS, Sardenberg J, Gu T, Aukhil I. Distinctive genes and signaling pathways associated with type 2 diabetes-related periodontitis: Preliminary study. *Plos one*. 2024 Jan 19;19(1):e0296925.
18. Sun X, Li M, Xia L, Fang Z, Yu S, Gao J, Feng Q, Yang P. Alteration of salivary microbiome in periodontitis with or without type-2 diabetes mellitus and metformin treatment. *Scientific Reports*. 2020 Sep 21;10(1):15363.
19. Ugwu CN, Ugwu OP, Alum EU, Eze VH, Basajja M, Ugwu JN, Ogenyi FC, Ejemot-Nwadiaro RI, Okon MB, Egba SI, Uti DE. Medical preparedness for bioterrorism and chemical warfare: A public health integration review. *Medicine*. 2025 May 2;104(18):e42289.
20. Kido D, Mizutani K, Takeda K, Mikami R, Matsuura T, Iwasaki K, Izumi Y. Impact of diabetes on gingival wound healing via oxidative stress. *PLoS One*. 2017 Dec 21;12(12):e0189601.
21. Nibali L, Gkraniats N, Mainas G, Di Pino A. Periodontitis and implant complications in diabetes. *Periodontology* 2000. 2022 Oct;90(1):88-105.
22. Wu CZ, Yuan YH, Liu HH, Li SS, Zhang BW, Chen W, An ZJ, Chen SY, Wu YZ, Han B, Li CJ. Epidemiologic relationship between periodontitis and type 2 diabetes mellitus. *BMC oral health*. 2020 Jul 11;20(1):204.
23. Ugwu CN, Ugwu OP, Alum EU, Eze VH, Basajja M, Ugwu JN, Ogenyi FC, Ejemot-Nwadiaro RI, Okon MB, Egba SI, Uti DE. Sustainable development goals (SDGs) and resilient healthcare systems: Addressing medicine and public health challenges in conflict zones. *Medicine*. 2025 Feb 14;104(7):e41535.
24. Bala S, Kumari R. Assessment of effect of periodontal and prosthodontic therapy on glycemic control in patients with diabetes. *Journal of Pharmacy and Bioallied Sciences*. 2021 Nov 1;13(Suppl 2):S1561-3.
25. Munjal A, Jain Y, Kote S, Krishnan V, Fahim R, Metha SS, Passi D. A study on the change in HbA1c levels before and after non-surgical periodontal therapy in type-2 diabetes mellitus in generalized periodontitis. *Journal of family medicine and primary care*. 2019 Apr 1;8(4):1326-9.
26. Nagpal R, Yamashiro Y, Izumi Y. The two-way association of periodontal infection with systemic disorders: An overview. *Mediators of inflammation*. 2015;2015(1):793898.
27. Paul-Chima UO, Ugwu CN, Alum EU. Integrated approaches in nutraceutical delivery systems: optimizing ADME dynamics for enhanced therapeutic potency and clinical impact. *RPS Pharmacy and Pharmacology Reports*. 2024 Oct;3(4):rqae024.
28. Naiff P, Carneiro V, Guimarães MD. Importance of mechanical periodontal therapy in patients with diabetes type 2 and periodontitis. *International journal of dentistry*. 2018;2018(1):6924631.
29. Kavya G, Reddy MN, Muthukuru RA. Assessment of the Awareness among Diabetic Patients of Their Risk for Oral Disease as Complication Associated With Diabetics. *Int Health Res J*. 2018;2(9):217-22.
30. Han SJ, Son YJ, Kim BH. Association between diabetes mellitus and oral health status in patients with cardiovascular diseases: A nationwide population-based study. *International Journal of Environmental Research and Public Health*. 2021 May 4;18(9):4889.
31. Maryniuk MD, Evert A, Rizzotto JA. Evidence and implementation of medical nutrition therapy in persons with diabetes. In *The Diabetes Textbook: Clinical Principles, Patient Management and Public Health Issues* 2019 Jun 28 (pp. 477-483). Cham: Springer International Publishing.
32. Bissett SM, Stone KM, Rapley T, Preshaw PM. An exploratory qualitative interview study about collaboration between medicine and dentistry in relation to diabetes management. *BMJ open*. 2013 Jan 1;3(2):e002192.
33. Petropoulou P, Kalemikerakis I, Dokoutsidou E, Evangelou E, Konstantinidis T, Govina O. Oral health education in patients with diabetes: a systematic review. In *Healthcare* 2024 Apr 26 (Vol. 12, No. 9, p. 898). MDPI.
34. Nazir MA, AlGhamdi L, AlKadi M, AlBeajan N, AlRashoudi L, AlHussan M. The burden of diabetes, its oral complications and their prevention and management. *Open access Macedonian journal of medical sciences*. 2018 Aug 15;6(8):1545.
35. Anyanwu C, Ibelegbu C, Ugwu C, Okonkwo V, Mgbemene C. Comparative evaluation of mesh sieve performance of a wet cereal slurry sieving machine. *Agricultural Engineering International: CIGR Journal*. 2021 Mar 26;23(1):115-27.
36. Katagiri S, Nagasawa T, Kobayashi H, Takamatsu H, Bharti P, Izumiyama H, Uchimura I, Tagami T, Suzuki T, Nanbara H, Taniguchi Y. Improvement of glycemic control after periodontal treatment by resolving gingival inflammation in type 2 diabetic patients with periodontal disease. *Journal of diabetes investigation*. 2012 Aug;3(4):402-9.
37. Paurobally N, Kruger E, Tennant M. Awareness about the oral and systemic complications of diabetes among a cohort of diabetic patients of the republic of Mauritius. *international dental journal*. 2021 Oct 1;71(5):438-48.
38. Mahtani AA, Jacob C, Lakshmanan R. Prevalence of diabetes among patients and the assessment of the awareness of the bidirectional relation between diabetes and periodontal disease. *Journal of Family Medicine and Primary Care*. 2020 Jun 1;9(6):2774-80.
39. Dagli N, Haque M, Kumar S. The interplay between diabetes and oral health: a comprehensive bibliometric analysis of clinical trials (1967-2024). *Cureus*. 2024 Apr 20;16(4).
40. Rapone B, Corsalini M, Converti I, Loverro MT, Gnoni A, Trerotoli P, Ferrara E. Does periodontal inflammation affect type 1 diabetes in childhood and adolescence? A meta-analysis. *Frontiers in Endocrinology*. 2020 May 5;11:278.
41. Orlando VA, Johnson LR, Wilson AR, Maahs DM, Wadwa RP, Bishop FK, Dong F, Morrato EH. Oral health knowledge and behaviors among adolescents with type 1 diabetes. *International journal of dentistry*. 2010;2010(1):942124.
42. Pukkila J, Mustaniemi S, Lingaiah S, Lappalainen OP, Kajantie E, Pouta A, Kaaja R, Eriksson JG, Laivuori H, Gissler M, Väärasmäki M. Increased Oral Care Needs and Third Molar Symptoms in Women with Gestational Diabetes

- Mellitus: A Finnish Gestational Diabetes Case–Control Study. *International Journal of Environmental Research and Public Health*. 2022 Aug 28;19(17):10711.
43. Crusell MK, Brink LR, Nielsen T, Allin KH, Hansen T, Damm P, Lauenborg J, Hansen TH, Pedersen O. Gestational diabetes and the human salivary microbiota: a longitudinal study during pregnancy and postpartum. *BMC pregnancy and childbirth*. 2020 Jan 31;20(1):69.
  44. Poudel P, Griffiths R, Arora A, Wong VW, Flack JR, Barker G, George A. Oral health status, knowledge, and behaviours of people with diabetes in Sydney, Australia. *International journal of environmental research and public health*. 2021 Mar 26;18(7):3464.
  45. Verhulst MJ, Teeuw WJ, Gerdes VE, Loos BG. Self-reported oral health and quality of life in patients with type 2 diabetes mellitus in primary care: a multi-center cross-sectional study. *Diabetes, metabolic syndrome and obesity: targets and therapy*. 2019 Jun 18:883-99.
  46. Linabarger M, Brown M, Patel N. A pilot study of integration of medical and dental care in 6 states. *Preventing Chronic Disease*. 2021 Jul 22;18:E72.
  47. Glurich I, Berg R, Panny A, Shimpi N, Steinmetz A, Nycz G, Acharya A. Longitudinal observation of outcomes and patient access to integrated care following point-of-care glycemic screening in community health center dental safety net clinics. *Frontiers in oral health*. 2021 May 26;2:670355.
  48. Bissett SM, Stone KM, Rapley T, Preshaw PM. An exploratory qualitative interview study about collaboration between medicine and dentistry in relation to diabetes management. *BMJ open*. 2013 Jan 1;3(2):e002192.
  49. Okon MB, Ugwu OP, Ugwu CN, Ogenyi FC, Swase DT, Anyanwu CN, Eze VH, Ugwu JN, Akinola SA, Mujinya R, Anyanwu EG. From pandemics to preparedness: harnessing AI, CRISPR, and synthetic biology to counter biosecurity threats. *Frontiers in Public Health*. 2025 Nov 26;13:1711344.
  50. Ugwu OP, Ogenyi FC, Ugwu CN, Basajja M, Okon MB. Mitochondrial stress bridge: Could muscle-derived extracellular vesicles be the missing link between sarcopenia, insulin resistance, and chemotherapy-induced cardiotoxicity?. *Biomedicine & Pharmacotherapy*. 2025 Dec 1;193:118814.
  51. Annamalai A, Tek C. An overview of diabetes management in schizophrenia patients: office based strategies for primary care practitioners and endocrinologists. *International journal of endocrinology*. 2015;2015(1):969182.
  52. Kremers SH, Wild SH, Elders PJ, Beulens JW, Campbell DJ, Pouwer F, Lindekilde N, de Wit M, Lloyd C, Rutters F. The role of mental disorders in precision medicine for diabetes: a narrative review. *Diabetologia*. 2022 Nov;65(11):1895-906.
  53. Ugwu CN, Ugwu OP, Alum EU, Eze VH, Basajja M, Ugwu JN, Ogenyi FC, Ejemot-Nwadiaro RI, Okon MB, Egba SI, Uti DE. Sustainable development goals (SDGs) and resilient healthcare systems: Addressing medicine and public health challenges in conflict zones. *Medicine*. 2025 Feb 14;104(7):e41535.
  54. Ongesa TN, Ugwu OP, Ugwu CN, Alum EU, Eze VH, Basajja M, Ugwu JN, Ogenyi FC, Okon MB, Ejemot-Nwadiaro RI. Optimizing emergency response systems in urban health crises: A project management approach to public health preparedness and response. *Medicine*. 2025 Jan 17;104(3):e41279.
  55. Ugwu CN, Ugwu OP, Alum EU, Eze VH, Basajja M, Ugwu JN, Ogenyi FC, Ejemot-Nwadiaro RI, Okon MB, Egba SI, Uti DE. Medical preparedness for bioterrorism and chemical warfare: A public health integration review. *Medicine*. 2025 May 2;104(18):e42289.
  56. Basiri R, Seidu B, Rudich M. Exploring the interrelationships between diabetes, nutrition, anxiety, and depression: implications for treatment and prevention strategies. *Nutrients*. 2023 Sep 30;15(19):4226.
  57. Paul-Chima UO, Nneoma UC, Bulhan S. Metabolic immunobridge: Could adipose-derived extracellular vesicles be the missing link between obesity, autoimmunity, and drug-induced hepatotoxicity?. *Medical Hypotheses*. 2025 Sep 28;111776.
  58. Yadav S, Hong YR, Westen S, Marlow NM, Haller MJ, Walker AF. Sociodemographic factors associated with major depressive episodes and suicidal ideation among emerging adults with diabetes in the US. *Frontiers in endocrinology*. 2023 Dec 7;14:1276336.
  59. Ugwu OP, Alum EU, Ugwu JN, Eze VH, Ugwu CN, Ogenyi FC, Okon MB. Harnessing technology for infectious disease response in conflict zones: Challenges, innovations, and policy implications. *Medicine*. 2024 Jul 12;103(28):e38834.
  60. Sweileh WM. Analysis of global research output on diabetes depression and suicide. *Annals of general psychiatry*. 2018 Oct 23;17(1):44.
  61. Mason J, Meal A, Shaw I, Adams GG. Outcomes of mindfulness-based stress reduction and mindfulness-based cognitive therapy in adults with diabetes: a systematic review. *Diabetes Treat*. 2018;10:2574-7568.
  62. Paul-Chima UO, Ugwu CN, Alum EU. Integrated approaches in nutraceutical delivery systems: optimizing ADME dynamics for enhanced therapeutic potency and clinical impact. *RPS Pharmacy and Pharmacology Reports*. 2024 Oct;3(4):rqae024.
  63. Ugwu OP, Ogenyi FC, Ugwu CN, Ugwu MN. Gut microbiota-derived metabolites as early biomarkers for childhood obesity: A policy commentary from urban African populations. *Obesity Medicine*. 2025 Sep 1;57:100641.

64. Isaac Edyedu PMA, Ugwu OPC, Ugwu CN, Alum EU, et al. The role of pharmacological interventions in managing urological complications during pregnancy and childbirth: A review. *Medicine*. 2025;104(7):e41381.
65. Alum EU, Ugwu OPC, Obeagu EI, et al. Nutritional care in diabetes mellitus: A comprehensive guide. *Int J Innov Appl Res*. 2023;11(12):16-25.
66. Obeagu EI, Ahmed YA, Obeagu GU, Bunu UO, Ugwu OPC, Alum EU. Biomarkers of breast cancer: Overview. *Int J Curr Res Biol Med*. 2023;1:8-16.
67. Uti DE, Alum EU, Atangwho IJ, Ugwu OPC, et al. Lipid-based nano-carriers for the delivery of anti-obesity natural compounds: Advances in targeted delivery and precision therapeutics. *J Nanobiotechnol*. 2025;23:336.
68. Ugwu CN, Ugwu OPC, Alum EU, Eze VHU, Basajja M, Ugwu JN, Ogenyi FC, et al. Medical preparedness for bioterrorism and chemical warfare: A public health integration review. *Medicine*. 2025;104(18):e42289.
69. Obeagu EI, Scott GY, Amekpor F, Ugwu OPC, Alum EU. COVID-19 infection and diabetes: A current issue. *Int J Innov Appl Res*. 2023;11(1):25-30.
70. Offor CE, Ugwu OPC, Alum EU. Anti-diabetic effect of ethanol leaf extract of *Allium sativum* on albino rats. *Int J Pharm Med Sci*. 2014;4(1):1-3.
71. Asogwa FC, Okechukwu PCU, Esther UA, Chinedu OE, Nzubechukwu E. Hygienic and sanitary assessment of street food vendors in selected towns of Enugu North District, Nigeria. *Am-Eurasian J Sci Res*. 2015;10(1):22-26.
72. Alum EU, Uti DE, Agah VM, Orji OU, Nkeiru N, et al. Physico-chemical and bacteriological analysis of water used for drinking and domestic purposes in Amaozara Ozizza, Afikpo North, Nigeria. *Niger J Biochem Mol Biol*. 2023;38(1):1-8.
73. Ugwu OPC, Alum EU, Okon MB, Obeagu EI. Mechanisms of microbiota modulation: Implications for health, disease, and therapeutic interventions. *Medicine*. 2024;103(19):e38088.
74. Ezekwe CI, Uzomba CR, Ugwu OPC. Effect of methanol extract of *Talinum triangulare* on hematology and liver parameters in rats. *Glob J Biotechnol Biochem*. 2013;8(2):51-60.
75. Alum EU, Inya JE, Ugwu OPC, Obeagu EI, Alope C, Aja PM, Okpata MG, et al. Ethanolic leaf extract of *Datura stramonium* attenuates methotrexate-induced biochemical alterations in Wistar rats. *RPS Pharmacol Rep*. 2023;2(1):1-6.
76. Ugwu OPC, Erisa K, Inyangat R, Obeagu EI, et al. Indigenous medicinal plants for managing diabetes in Uganda: Ethnobotanical and pharmacotherapeutic insights. *INOSR Exp Sci*. 2023;12(2):214-224.
77. Alum EU, Aja W, Ugwu OPC. Vitamin composition of ethanol leaf and seed extracts of *Datura stramonium*. *Avicenna J Med Biochem*. 2023;11(1):92-97.
78. Ezenwaji CO, Alum EU, Ugwu OPC. Digital health in pandemic preparedness and response: Securing global health? *Glob Health Action*. 2024;17(1):2419694.
79. Adonu CC, Ugwu OP, Bawa A, Ossai EC, Nwaka AC. Intrinsic blood coagulation studies in patients with diabetes and hypertension. *Int J Pharm Med Bio Sci*. 2013;2(2):36-45.
80. Offor CE, Ugwu PC, Okechukwu PM, Igwenyi IO. Proximate and phytochemical analyses of *Terminalia catappa* leaves. *Eur J Appl Sci*. 2015;7(1):9-11.
81. Enechi YS, Ugwu OC, Ugwu KK, Ugwu OPC, Omeh N. Evaluation of antinutrient levels of *Ceiba pentandra* leaves. *IJRRPAS*. 2013;3(3):394-400.
82. Alum EU, Uti DE, Ugwu OPC, Alum BN, Edeh FO, Ainebyoona C. Microbiota in cancer development and treatment. *Discov Oncol*. 2025;16(1):646.
83. Asogwa FC, Okoye COB, Ugwu OPC, Edwin N, Alum EU, Egwu CO. Phytochemistry and antimicrobial assay of *Jatropha curcas* extracts. *Eur J Appl Sci*. 2015;7(1):12-16.
84. Enechi OC, Oluka HI, Ugwu PCO. Acute toxicity and ameliorative properties of *Alstonia boonei* leaf extract on diabetic rats. *Afr J Biotechnol*. 2014;13(5).
85. Alum EU, Obeagu EI, Ugwu OPC. Enhancing water, sanitation, and hygiene for diarrhoea control and SDGs: A review. *Medicine*. 2024;103(38):e39578.
86. Odo CE, Nwodo OFC, Joshua PE, Ugwu OPC, Okonkwo CC. Anti-diarrhoeal effect of chloroform-methanol extract of *Persea americana* seeds in rats. *J Pharm Res*. 2013;6(3):331-335.
87. Ugwu OPC, Obeagu EI, Alum EU, Michael M, et al. Effect of ethanol leaf extract of *Chromolaena odorata* on hepatic markers in diabetic rats. *IAA J Appl Sci*. 2023;9(1):46-56.
88. Ibiham UA, Alum EU, Orji OU, Aja PM, Nwamaka EN, Ugwu OPC, et al. Anti-inflammatory effects of *Buchholzia coriacea* leaf extract in arthritic rats. *Indo Am J Pharm Sci*. 2018;5(7):6341-6357.
89. Obeagu EI, Obeagu GU, Odo EO, Alum EU. Nutritional approaches for enhancing immune competence in HIV-positive individuals. *IDOSR J Appl Sci*. 2024;9(1):40-50.

90. Obeagu EI, Alum EU, Ugwu OPC. Hepcidin: Gatekeeper of iron in malaria resistance. *Newport Int J Res Med Sci.* 2023;4(2):1-8.
91. Nyamboga TO, Ugwu OPC, Ugwu JN, et al. Biotechnological innovations in soil health management: a systematic review of integrating microbiome engineering, bioinformatics, and sustainable practices. *Cogent Food Agric.* 2025;11(1):2519811.
92. Madu ANB, Alum EU, Aloh HE, Ugwu OPC, Obeagu EI, Uti DE, Egba SI, Ukaidi CUA. The price of progress: Assessing the financial costs of HIV/AIDS management in East Africa. *Medicine.* 2025;104(18):e42300.
93. Alum EU, Ugwu OPC. Beyond pregnancy: Understanding long-term implications of gestational diabetes mellitus. *INOSR Sci Res.* 2024;11(1):63-71.
94. Ugwu OPC, Alum EU, Okon MB, Aja PM, Obeagu EI, Onyeneke EC. Anti-nutritional and GC-MS analysis of ethanol root extract and fractions of *Sphenocentrum jollyanum*. *RPS Pharmacol Pharm Rep.* 2023;2(2):rqad007.
95. Eze VHU, Eze CE, Mbabazi A, Ugwu CN, Ugwu PO, Ogenyi CF, Ugwu JN, et al. Qualities and characteristics of a good scientific research writing: Step-by-step approaches. *IAA J Appl Sci.* 2023;9(2):71-76.
96. Igwenyi IO, Nchi PO, Okechukwu UPC, Igwenyi IP, Obasi DC, Edwin N. Nutritional potential of *Azadirachta indica* seeds. *Indo Am J Pharm Sci.* 2017;4(2):477-482.
97. Enechi OC, Oluka IH, Ugwu OPC, Omeh YS. Effect of ethanol leaf extract of *Alstonia boonei* on lipid profile of alloxan-induced diabetic rats. *Afr J Biotechnol.* 2013;24.
98. Ugwu OPC. Anti-malaria effect of ethanol extract of *Moringa oleifera* leaves on malaria-induced mice. *University of Nigeria Nsukka;* 2011:39.
99. Alum EU, Ugwu OPC, Obeagu EI. Nutritional interventions for cervical cancer patients: Beyond conventional therapies. *J Cancer Res Cell Ther.* 2024;8(1):1-6.
100. Obeagu EI, Obeagu GU. Advancements in immune augmentation strategies for HIV patients. *IAA J Biol Sci.* 2024;11(1):1-11.
101. Okechukwu PU, Nzubechukwu E, Ogbanshi ME, Ezeani N, Nworie MO. Effect of ethanol leaf extract of *Jatropha curcas* on chloroform-induced hepatotoxicity in albino rats. *Glob J Biotech Biochem.* 2015;10:11-15.
102. Ilozue NM, Ikezu UP, Okechukwu PCU. Antimicrobial and phytochemical screening of *Persea americana* seed extracts. *IOSR J Pharm Biol Sci.* 2014;9(2):23-25.
103. Onyeze R, Udeh SM, Akachi B, Ugwu OP. Isolation and characterization of fungi associated with spoilage of corn (*Zea mays*). *Int J Pharm Med Biol Sci.* 2013;2(3):86-91.
104. Obeagu EI, Alum EU, Ugwu OPC. Hepcidin: The gatekeeper of iron in malaria resistance. *Newport Int J Res Med Sci.* 2023;4:1-8.
105. Obeagu EI, Alum EU, Obeagu GU, Ugwu OPC. Prostate cancer: Review on risk factors. *Eurasian Exp J Public Health.* 2023;4(1):4-7.
106. Ofor CE, Okaka ANC, Ogbugo SO, Egwu CO, Okechukwu PC. Effects of ethanol leaf extract of *Pterocarpus santalinoides* on haemoglobin, packed cell volume and platelets. *IOSR J Nurs Health Sci.* 2015;4:108-112, 93.
107. Ofor C, Aja PC, Ugwu O, Agbafor KN. Effects of ethanol leaf extract of *Gmelina arborea* on serum proteins in albino rats. *Glob J Environ Res.* 2015;9(1):1-4.
108. Alum EU, Uti DE, Obeagu EI, Ugwu OPC, Alum BN. Cancer's psychosocial aspects: Impact on patient outcomes. *Elite J Med.* 2024;2(6):32-42.
109. Alum EU, Ugwu OPC, Egba SI, Uti DE, Alum BN. Climate variability and malaria transmission: Unravelling the complex relationship. *INOSR Sci Res.* 2024;11(2):16-22.
110. Alum EU, Obeagu EI, Ugwu OPC, Egba SI, EjimUti DE, Ukaidi CUA, et al. Confronting dual challenges: Substance abuse and HIV/AIDS. *Elite J HIV.* 2024;2(5):1-8.

**CITE AS: Arionget Jemima (2026). Diabetes and Oral Health: Evidence, Mechanisms, and Clinical Implications. IAA Journal of Scientific Research 13(1):41-54.**  
<https://doi.org/10.59298/IAAJSR/2026/1314154>